ONWARD Medical Reports First Quarter 2026 Results with Strong Commercial Momentum
Summary
ONWARD Medical reported first quarter 2026 results including supply of 70 ARC-EX Systems, with the therapy now available in over 100 clinics across the US and Europe. The company announced first participant enrollment and implant in the Empower BP global pivotal study for blood pressure instability after spinal cord injury, with 12 US sites activated. Two additional individuals received investigational ARC-BCI Therapy, the world's first purpose-designed platform pairing a BCI with implantable spinal cord stimulation. Revenue reached EUR 2.0 million with a post-raise cash balance extending runway into Q1 2028.
Why it matters
ONWARD's progress across multiple platforms simultaneously, external spinal cord stimulation, implantable systems, and BCI-spinal cord pairing, demonstrates the breadth of neurotechnology applications for spinal cord injury. The company's commercial traction with ARC-EX and advancement of its pivotal study positions it as a leader in translating decades of neuroscience research into therapies that restore movement, function, and independence.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial